A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

What this study is about

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Who can join (things the study team will check)

✅ You may be able to join if…

• Moderate-to-severe AD
• Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable
• Female participants who are not pregnant or breastfeeding and meet at least one of the following conditions: not of childbearing potential or of childbearing potential and agrees to use a highly effective method of contraception
• Male participants must agree to use a highly effective method of contraception
• EASI score ≥16
• vIGA-AD score ≥3
• ≥10% body surface area (BSA) of AD involvement
• Mean peak pruritus numerical rating scale ≥ 4 during 7-days before randomization

🚫 You may not be able to join if…

• Positive hepatitis B, hepatitis C, or human immunodeficiency virus infection
• Evidence of active or latent tuberculosis (TB)
• History of untreated or inadequately treated TB infection
• Active infection requiring treatment with systemic antibiotics, antivirals, antifungals, antiparasitics or antiprotozoals
• Active unstable pruritic skin conditions in addition to AD that would interfere with the assessment of AD based on the investigator's clinical judgement
• Other conditions or laboratory abnormality that could increase the risk associated with study participation or could interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into the study
• Having received any of the specified therapies within the specified timeframe(s) prior to the Baseline visit

Where this trial is running

• Inmagene Site 1, Lancaster, California, United States
• Inmagene Site 23, Los Angeles, California, United States
• Inmagene Site 19, Ocala, Florida, United States
• Inmagene Site 4, Tampa, Florida, United States
• Inmagene Site 2, Rolling Meadows, Illinois, United States
• Inmagene Site 6, Kew Gardens, New York, United States
• Inmagene Site 21, New York, New York, United States
• Inmagene Site 11, Woodbury, New York, United States
• Inmagene Site 20, Charlotte, North Carolina, United States
• Inmagene Site 10, Fargo, North Dakota, United States
• Inmagene Site 9, Columbus, Ohio, United States
• Inmagene Site 5, Mayfield Heights, Ohio, United States

+ 11 more sites.

Who to contact

ADAPTIVE Study Lead · (858) 345-6927 · ADAPTIVE_StudyLead@imagenebio.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07037901.